Bayer Healthcare Pharmaceuticals must continue to litigate allegations that it misrepresented the efficacy of its statin drug Baycol in a lawsuit dating back to 2006 (United States ex rel. Simpson v. Bayer Healthcare, 2017 BL 316206, 8th Cir., No. 15-2220, 9/8/17).
The U.S. Court of Appeals for the Eighth Circuit reversed a 2015 dismissal of whistle-blower Laurie Simpson’s lawsuit against Bayer in a Sept. 8 decision. Simpson alleged the drugmaker fraudulently induced the Department of Defense to purchase more than $11 million worth of Baycol (cerivastatin) by misrepresenting its effectiveness and associated patient risks versus comparable drugs. Simpson, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.